HIGH-RISK NEUROBLASTOMA

This study tests whether adding the drug naxitamab to standard chemotherapy helps children with newly diagnosed high-risk neuroblastoma. About 93 children will receive naxitamab during their first 5 rounds of chemo. The goal is to see if this combination leads to more complete re…

This study tests whether adding an antibody drug called hu14.18K322A to standard chemotherapy helps shrink or eliminate high-risk neuroblastoma in children and teens aged 1.5 to 18 years. Neuroblastoma is a rare but aggressive solid tumor that often spreads before diagnosis. The …

This early-stage trial tests a new treatment for children with neuroblastoma that has come back or is hard to treat. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer. The main goal is to find a safe dose and understand side effects. Up …

This study tests a new treatment called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and atta…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two proteins on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has returned or not responded to standard treatments. The goal is to find a safe do…

This study tests a reduced chemotherapy plan called N10 for children with high-risk neuroblastoma. The goal is to see if it works well and is safe enough to shrink tumors early. About 45 children under 19 with newly diagnosed high-risk neuroblastoma will take part.

This study is for children with high-risk neuroblastoma whose cancer is in complete remission. It tests a bivalent vaccine (with an immune booster called OPT-821) plus an oral supplement called β-glucan to see which schedule of β-glucan works best to strengthen the immune system …

This early-phase trial tests a new treatment called GPC2 CAR T cells for children with advanced neuroblastoma or retinoblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and at…

This study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…

This study looks at whether adding a special support program (called RISE) to usual care can reduce money-related stress for low-income families whose child has high-risk neuroblastoma. About 84 children and their parents will take part, with some getting the extra support and ot…